Text Size

The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients’ Lipid Profiles

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2006 by China Medical University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT00316641
First received: April 20, 2006
Last updated: November 6, 2006
Last verified: March 2006
History of Changes
  Purpose

The purpose of this study is to determine whether the Lipid-lowing Tea is effective and safe in the treatment of Hyperlipidemia Patients


Condition Intervention Phase
Hyperlipidemia
 Drug: Lipid-lowing Tea
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind

Further study details as provided by China Medical University Hospital:

  Eligibility

Ages Eligible for Study:   20 Years to 65 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Patient aged 20-65 years;either sex
  • Patient diagnosed with hyperlipidemia(fasting levels of TC>=200mg/dL),or TG>=200mg/dL but <400mg/dL,or LDL-C>=130mg/dL)
  • Patient who has signed the informed consent form

Exclusion Criteria:

  • Patient with pregnancy (or child bearing potential),or in lactation
  • Patient with any lipid regulating agents within 4 weeks prior to study period
  • Patient currently taking concomitant medications, such as oral contraceptives, or any medical treatment capable of interfering with lipid metabolism(eg thiazides, β-blockers, cyclosporins, itraconazole erythromycin,and danazol)
  • Patient with medical history of hypothyroidism, pancreatitis, cholestasis, nephrotic syndrome, gall bladder disease, primary biliary cirrhosis.
  • Patient with liver dysfunction (SGOT or SGPT>2x ULN)
  • Patient with renal insufficiency (serum creatinine>1.3mg/dL)
  • Patient with myocardial infarction,cerebrovascular disease,or major operations within 6 months prior to the study period.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00316641

Contacts
Contact: Chia-I Tsai, V.S 886-4-22052121 ext 5065 josepho777@yahoo.com.tw

Locations
Taiwan
China Medical University Hospital Recruiting
Taichung, Taiwan, 404
Contact: Chia-I Tsai, MD     886-4-22052121 ext 5065     josepho777@yahoo.com.tw    
Principal Investigator: Chia-I Tsai, MD            
Sponsors and Collaborators
China Medical University Hospital
Investigators
Principal Investigator: Chia-I Tsai, V.S China Medical University Hospital,Taichung,Taiwan
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00316641     History of Changes
Other Study ID Numbers: DMR93-IRB-71
Study First Received: April 20, 2006
Last Updated: November 6, 2006
Health Authority: Taiwan: Institutional Review Board

Additional relevant MeSH terms:
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on May 19, 2013